Related Experiment Video
Updated: Jan 28, 2026
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Human Galectin-1 and Its Inhibitors: Privileged Target for Cancer and HIV
Narella Sridhar Goud1, P S Lakshmi Soukya1, Mahammad Ghouse1
1Department of Medicinal Chemistry, National Institute of pharmaceutical Education and Research (NIPER) - Hyderabad, Balanagar, 500037, India.
Abstract:
Galectin 1(Gal-1), a β-galactoside binding mammalian lectin of 14KDa, is implicated in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape. Gal-1 is considered as a biomarker in diagnosis, prognosis and treatment condition. The overexpression of Gal-1 is well established and seen in many types of cancer progression like osteosarcoma, breast, lung, prostate, melanoma, etc. Gal-1 greatly accelerates the binding kinetics of HIV-1 to susceptible cells, leading to faster viral entry and a more robust viral replication by specific binding of CD4 cells. Hence, the Gal-1 is considered a promising molecular target for the development of new therapeutic drugs for cancer and HIV. The present review laid emphasis on structural insights and functional role of Gal-1 in the disease, current Gal-1 inhibitors and future prospects in the design of specific Gal-1 inhibitors.
Insights
Galectin 1 (Gal-1) is a key protein in cancer and HIV progression. Inhibiting Gal-1 offers a promising therapeutic strategy for these diseases.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Galectin 1 (Gal-1) is a beta-galactoside binding lectin involved in signaling pathways and immune responses.
- Overexpression of Gal-1 is linked to cancer progression (e.g., osteosarcoma, breast, lung, prostate, melanoma) and immune disorders.
- Gal-1 also accelerates HIV-1 binding and replication by interacting with CD4 cells.
Purpose of the Study:
- To review the structural insights and functional roles of Gal-1 in disease pathogenesis.
- To discuss current Gal-1 inhibitors and their therapeutic potential.
- To explore future prospects in designing specific Gal-1 inhibitors.
Main Methods:
- Literature review focusing on Gal-1's role in cancer and HIV.
- Analysis of Gal-1's involvement in biological functions like apoptosis, angiogenesis, and immune escape.
- Examination of existing Gal-1 inhibitors and drug design strategies.
Main Results:
- Gal-1 significantly contributes to tumor development, metastasis, and immune evasion.
- Gal-1 enhances HIV-1 entry and replication.
- Gal-1 is a validated biomarker for cancer diagnosis, prognosis, and treatment monitoring.
Conclusions:
- Inhibition of Gal-1 presents a potential therapeutic avenue for cancer and HIV treatment.
- Targeting Gal-1 is a promising strategy for developing novel anti-cancer and anti-HIV drugs.
- Further research into specific Gal-1 inhibitors is warranted for clinical applications.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
07:22A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:23Dipeptidyl Peptidase 4 Inhibitors
02:15SN1 Reaction: Stereochemistry
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
02:05SN1 Reaction: Kinetics
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
02:25SN1 Reaction: Mechanism
Firstly, the haloalkane ionizes to generate a carbocation intermediate and a halide ion. This heterolytic cleavage is highly endothermic with large activation energy. The ionization of the substrate, facilitated by a...